Filing Flows › Arcutis Biotherapeutics (ARQT) › Q1 2026
Arcutis Biotherapeutics (ARQT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Arcutis Biotherapeutics (ARQT) reported revenue of $105M for the first quarter 2026 (Q1 2026), +60% from a year earlier and -19% from the quarter before. Operating margin was -8.6%, net loss $11.3M (10.7% of revenue).
Arcutis Biotherapeutics, Q1 2026: revenue $105M (+60% year over year), operating margin -8.6%, net loss $11.3M, operating cash flow $2.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $105M | -19% | +60% |
| Operating profit | −$9.1M | -149% | — |
| Net earnings | −$11.3M | -165% | — |
| Operating cash flow | $2.2M | -91% | — |
What changed
Revenue was $105.4M in Q1 2026, up 60% year over year and down 19% from the previous quarter. ZORYVE foam was the largest line at 47% of revenue. ZORYVE foam added $19.4M year over year (up 64%), 49% of the total change.
Operating costs exceeded revenue by $9.1M, an operating margin of -8.6%. Total costs grew 27% against revenue growth of 60%. The fastest-growing cost line was Research & development (+75%). The quarter ended with a net loss of $11.3M, after a profit of $17.4M the previous quarter.
Operating cash flow was $2.2M. Non-cash charges added back $10.7M of share-based compensation. Working capital and other items added $2.8M.
Questions
What was Arcutis Biotherapeutics' revenue in the first quarter 2026?
Arcutis Biotherapeutics (ARQT) reported revenue of $105M for the first quarter 2026 (Q1 2026), +60% from a year earlier and -19% from the quarter before.
Was Arcutis Biotherapeutics profitable in the first quarter 2026?
Operating loss was $9.1M (-8.6% of revenue) and net loss $11.3M.